Irina Gutyryak/iStock via Getty Images
Tilray brands (NASDAQ:TLRY) announced Thursday that regulators in Portugal approved THC 5 CBD 20, paving the way for the Canadian marijuana company to launch its first approved medical cannabis extract in the country.
“This is a monumental step forward for patient care in Portugal,” said Denise Faltischek, strategy director at TLRY.
The decision confirmed Monday allows the company to launch oral THC 5 CBD 20 in late spring, Tilray (TLRY) said, adding that the product is indicated for several critical areas of healthcare.
“With the approval of our first medicinal cannabis extract, we are proud to be at the forefront of medical cannabis research and accessibility and continue to demonstrate our commitment to providing innovative, safe and effective therapeutic options to patients,” Faltischek added.
